UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/791,628	03/01/2004	Benjamin G. Davis	GC571-2-C1	3111
Genencor Intern	7590 01/27/200 national, Inc.	EXAMINER		
925 Page Mill Road			MEAH, MOHAMMAD Y	
Palo Alto, CA 94034-1013			ART UNIT	PAPER NUMBER
			1652	
			MAIL DATE	DELIVERY MODE
			01/27/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
	10/791,628	DAVIS ET AL.			
Office Action Summary	Examiner	Art Unit			
	MD. YOUNUS MEAH	1652			
The MAILING DATE of this communication app	ears on the cover sheet with the c	orrespondence address			
Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	lely filed the mailing date of this communication. (35 U.S.C. § 133).			
Status					
 1) Responsive to communication(s) filed on 19 Second 2a) This action is FINAL. 2b) This 3) Since this application is in condition for allowant closed in accordance with the practice under Expression 	action is non-final. nce except for formal matters, pro				
Disposition of Claims					
4) ☐ Claim(s) 1-5,8-10,19-23,25,26,32-40,44-47,56-4a) Of the above claim(s) 37-40,44-47,56-60,62 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1-5,8-10,19-23,25,26 and 32-36 is/are 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or	2 <u>,63 <i>and</i> 69-70, 72-73</u> is/are witho	•			
Application Papers					
9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the of Replacement drawing sheet(s) including the correction of the original origina	epted or b) objected to by the Edrawing(s) be held in abeyance. See on is required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	ite			

Application/Control Number: 10/791,628 Page 2

Art Unit: 1652

DETAILED ACTION

Claims 1-5, 8-10, 19-23, 25-26, 32-40, 44-47, 56-60, 62-63, 69-70 and 72-73 are

pending. With supplemental amendment of this application, the applicant, on dates

09/19/08 amended claims 1, 9-10, 20-23, 25-26, 32-36 and canceled claims 6, 7, 11-18,

24, 27-31, 41-43, 48-55, 61, 64-68 and 74-45. Claims 37-40, 44-47, 56-60, 62-63, 69-70

and 72-73 remain withdrawn. Claims 1-5, 8-10, 19-23, 25-26 and 32-36 are for

examination.

Claim Rejections

35 U.S.C 112

2nd paragraph rejection

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter, which the applicant regards as his

invention.

Claims 5, 8 and 33 is rejected under 35 U.S.C. 112, second paragraph, as being

indefinite for failing to particularly point out and distinctly claim the subject matter which

applicant regards as the invention.

Claim 5, the recitation of the phrase "near a subsite" renders the claim indefinite

because it is relative term.

Claims 33 is indefinite in the recitation of "lectin" as there is no antecedent basis

for lectin in claim 1, from which this claim depends.

35 U.S.C 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

Application/Control Number: 10/791,628 Page 3

Art Unit: 1652

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 9-10 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. These claims are directed subtillsin-type serine hydrolase comprising proteins by incorporation by reference to GENEBANK Accession Numbers. These are improper incorporations by reference (see MPEP 608.01(p) (c). Since the accession numbers in these claims are considered essential and GENEBANK is not a US patent or patent publication incorporation by reference to GENEBANK Accession Numbers is improper. Therefore the specification lacks the description of essential material. Given this lack of description of essential material encompassed by the claims, the specification fails to sufficiently describe the claimed invention in such full, clear, concise, and exact terms that a skilled artisan would recognize that applicants were in possession of the claimed invention. Therefore one of skill in the art would not recognize from the disclosure that applicants' were in possession of the claimed invention. Applicants' are referred to the revised guidelines concerning compliance with the written description requirement of U.S.C. 112, first paragraph, published in the Official Gazette and also available at www.uspto.gov.

CLAIM Rejection - 35 U.S.C 102

Art Unit: 1652

35 U.S.C 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

Claims 1-5, 8, 19-23, 25-26, 32-34 and 36 are rejected under 35 U.S.C. 102(a) as being anticipated by Davis, et al. (J. org. chem. 19998, pp 9614-9615).

Davis et al. teach *B. subtilisin* protease conjugated to carbohydrate such as mannose wherein cystine residue is introduced to S1 subsite by substitution (page 9614, column 2, 2nd parg) at a preselected position enabling the highly reactive thiol group to react with an activated carbohydrate moiety (page 9614, column 2 parg. 1). Enzyme conjugate comprising said protease conjugated to carbohydrate comprise binding ability to lectin, like conA and ability to cleave lectin molecule by protease domain. It is well known in the art that carbohydrate bind lectin, such as concanavalin A (conA), selectin and other cell surface carbohydrate binding proteins, including blood (blood comprise selectin) stain (soil) (see Wang et al. JBC 1975, 250, 1490-1502). ConA and other lectins are involved in the interaction of cell surface receptor and other ligands comprising glycoprotein (Wang et al. page 1490). It is well known in the art that subtilisins are broad specificity serine proteases and would be expected to cleave a

Art Unit: 1652

peptide bond in a target protein such as lectins or selectin (see Wang et al. page 1491, column 1, subtilisin protease cleave conA).

CLAIM Rejection - 35 U.S.C 103a

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a)A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claim 35 is rejected under 35 U.S.C. 103(a) as being unpatentable over Davis et al. (J. org. chem. 19998, pp 9614-9615).), in view of Nilsson et al (Glycoconjugate 1998, 219-223).

Davis et al. teach *B. subtilisin* protease conjugated to carbohydrate such as mannose wherein cystine residue is introduced to S1 subsite by substitution (page 9614, column 2, 2nd parg) at a pre-selected position enabling the highly reactive thiol group to react with an activated carbohydrate moiety (page 9614, column 2 parg. 1). However Davis et al. do not teach said mannoside as thioethyl mannoside.

Nilsson et al teach the use of thioethyl glycoside as building block in carbohydrate synthesis. Nilsson et al teach also teach the advantage of thioglycoside, such stable under most reaction condition, can be activated easily (page 219 1st parg.) Therefore, one knowledgeable in prior art is motivated to make chimeric protein comprising B. subtilisin protease conjugated to mannose via thioethyl mannoside.

As such it would have been obvious to one of ordinary skill in the art to use thioethyl mannoside to conjugate B. subtilisin type protease as taught by Davis et al.

Application/Control Number: 10/791,628 Page 6

Art Unit: 1652

Conclusion

Claims 1-5, 8-10, 19-23, 25-26.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mohammad Meah whose telephone number is 571-272-1261. The examiner can normally be reached on 8:30-5PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, NASHAAT T NASHED can be reached on 571-272-0934. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Mohammad Younus Meah Examiner, Art Unit 1652 Recombinant Enzymes, 3C31 Remsen Bld 400 Dulany Street, Alexandria, VA 22314 Telephone: 517-272-1261

/Nashaat T. Nashed/ Supervisory Patent Examiner, Art Unit 1652